Editorial

Dear Readers,

first of all: we would like to wish you and your family a happy, healthy and prosperous new year.

This year – 2019 – will be a very important year for Drug Research: it is the first year under a new editorship as Thomas Gudermann (Munich) and Matthias Schwab (Stuttgart) take over from Martin Wehling.

Professor Dr. Martin Wehling was Editor-in-Chief of Drug Research for well over a decade. He took up this position when the journal was still published by Editio Cantor Verlag, a publishing house specializing in pharmacological and pharmaceutical publications. When Thieme Group acquired the journal in 2011, Martin kindly accepted to remain Editor-in-Chief and he continued the great work he had been doing together with the old publisher, Norbert Schramm, for another 8 years. The move to Thieme offered the opportunity to refocus the journal, and Martin Wehling took the strategic decision to focus Drug Research on translational and clinical research – a decision that triggered rising numbers of manuscript submissions from an ever more international audience. We thank Martin for a great job, for his dedication and for the countless hours he has spent being the Editor-in-Chief of Drug Research.

This note though is, above all, about the future. And please join us in welcoming Thomas Gudermann and Matthias Schwab, our two new Editors-in-Chief of Drug Research. We are very happy to have two such outstanding scientists and medical experts in charge of our journal.

Professor Dr. Thomas Gudermann, who started his scientific career in endocrinology, is now a world-renowned specialist in the field of experimental pharmacology and toxicology. He is director of the distinguished Walther Straub Institute of Pharmacology and Toxicology of LMU Munich and is currently heading two large center grants in pharmacology and toxicology. Moreover, Thomas is also a seasoned editor – and we are very proud that for over 10 years he was Co-Editor-in-Chief of Experimental and Clinical Endocrinology & Diabetes.

Professor Dr. Matthias Schwab, a pediatrician and a clinical pharmacologist, is best known for his outstanding work in clinical pharmacology. He is director of the esteemed Fischer-Bosch Institute of Clinical Pharmacology, Professor and Chair for clinical pharmacology at the University of Tübingen as well as Clinical Director of Clinical Pharmacology at the University Hospital Tübingen. Besides, Matthias is a Clarivate Analytics Highly Cited Researcher and a very experienced editor – and we are delighted that he is now Co-Editor-in-Chief of Drug Research.

We are thrilled indeed to have Drug Research in their care and we wish them – and the journal, of course – the very best for the future!

The Publisher
Georg Thieme Verlag KG
Stuttgart